University of Vermont
Welcome,         Profile    Billing    Logout  
 13 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lewis, Michael I
NCT05040776: COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients

Withdrawn
2
90
US
EP-7041 Injection, EP-7041, Frunexian
eXIthera Pharmaceuticals
Thrombopenia, Covid19
05/24
05/25
SURE-AVR, NCT02679404: Sorin Universal REgistry on Aortic Valve Replacement

Terminated
N/A
2758
Europe, Canada, US, RoW
Corcym S.r.l
Aortic Valve Disease, Aortic Stenosis
03/21
03/21
Baptist, Alan
NCT04444895 / 2019-004823-20: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Completed
3
73
Europe, Canada, Japan, US
Lanadelumab, DX-2930, SHP643, TAK-743
Shire, Takeda Development Center Americas, Inc.
Angioedema
05/23
05/23
NCT04583007: Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

No Longer Available
N/A
Europe, Canada, US
Lanadelumab 150 mg, TAK-743, SHP643, DX-2930, Lanadelumab 300 mg
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE), Angioedema
 
 
RAPID, NCT04287621: Registry of Asthma Patients Initiating DUPIXENT®

Active, not recruiting
N/A
718
Europe, Canada, Japan, US
DUPIXENT®, dupilumab, REGN668, SAR231893
Regeneron Pharmaceuticals, Sanofi
Asthma
07/26
07/26
Meehan, Kathy
No trials found
Hodgdon, Kevin
No trials found
Weingarten, Jerem
No trials found
Raymond, Cory
No trials found

Download Options